Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M

ARROWHEAD PHARMACEUTICALS, INC.

Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.
Up to $160M in milestones: $50M on Phase 3 enrollment, $50M on FDA approval, $60M after annual royalty receipt threshold.
Arrowhead retains eligibility for all milestone payments from Amgen under the original license agreement.
Transaction provides non-dilutive cash to fund Arrowhead's pipeline and operations.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. entered into Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at up to $410 million (effective 2022-11-09).

Action: entry
Counterparty: Royalty Pharma Investments 2019 ICAV
Value: up to $410 million
Effective: 2022-11-09

Exact text from the filing

Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into a Royalty Purchase Agreement (the “Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), pursuant to which Royalty Pharma agreed to pay up to $410 million in cash to the Company

View on SEC.gov

Browse all material agreements →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-22-029456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.